生物制药公司Atossa Genetics Inc（纳斯达克代码：ATOS）近日宣布，其针对转移性乳腺癌研发的(Z)-Endoxifen新药临床试验申请已获得美国食品药品监督管理局（FDA）签发的"研究可继续进行"许可函。这一关键进展意味着该公司可以正式启动该药物的临床研究阶段。
该许可函标志着(Z)-Endoxifen在治疗转移性乳腺癌的研发道路上迈出重要一步。作为选择性雌激素受体调节剂，(Z)-Endoxifen有望为晚期乳腺癌患者提供新的治疗选择。FDA的批准为后续临床试验扫清了监管障碍，公司将按计划推进相关研究工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.